The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative to surgically remove the organ. ...

Accessibility StatementSkip Navigation First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction Potential practice-changing treatment for certain patients with BCG-unresponsive non-muscle invasive bladder cancer who have limited options before possible bladder removal RARITAN, N.J., Sept. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. ...

CHINA - 2025/09/04: In this photo illustration, Johnson & Johnson's logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded in durable business fundamentals, or is it a temporary market anomaly? The evid ...

Sep 8, 2025 6:17 PM Eastern Daylight Time "We are pleased to welcome John to our Company's Board of Directors,†said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to drive innovation will be an incredible asset to Johnson & Johnson as we continue to deliver the next generation of health ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available app. ...

Along with Materials, the Health Care sector bounced back in August . Still, the space is down by more than 12% from a year ago, easily the worst-performing of the 11 S&P 500 groupings. There are green shoots, however.Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to finan ...

Johnson & Johnson (NYSE: JNJ ) (NEOE: JNJ:CA ) is an American healthcare heavyweight with a major focus on pharma and medical devices. The company used to sell consumer health and skincare products directly, but with theDear Reader,I am a Senior Derivatives Expert with over 10 years of experience in the field of Asset Management, specializing in equity analysis and research, macroeconomics, and risk-managed portfolio construction. My professional background covers both institutional and private client asset ...

**行业与公司** * 行业专注于美国生物制药市场 涵盖处方药销售趋势、新产品上市表现及生物类似药竞争格局[1][6][7] * 涉及公司包括Bristol Myers Squibb (BMY)、Vertex (VRTX)、Gilead (GILD)、Eli Lilly (LLY)、Johnson & Johnson (JNJ)、Amgen (AMGN)、Pfizer (PFE)、Novo Nordisk (NVO)、AbbVie (ABBV)等主要制药企业[3][4][5][10][11][13] * 数据来源为IQVIA处方药销售数据库 涵盖品牌药、仿制药及生物类似药[28][36][40] **核心观点与论据** * 美国处方药市场总体增长放缓 截至8月29日当周总处方量(TRx)同比增长+1.7% 低于前周的+2.3%和过去12周平均的+2.6%[1][2] * 扩展单位(EUTRx)增长(+2.0%)高于TRx增长 表明医生更倾向于开具长期处方(如90天)[2][32][37] * BMY的Cobenfy(精神分裂症药物)周处方量2,210份 需达到竞争产品Rexulti/Caplyta/Lybalvi的2-3倍销量才能实现2025年1.71亿美元共识预期[3] * VRTX的Journavx(急性疼痛药物)周处方量7,280份 医院渠道占35%未计入IQVIA 需34.9万总处方量实现2025年7800万美元预期[4] * GILD的Yeztugo(HIV预防药物)周总处方量470份(注射剂240份) 专家调研显示初始采用集中于新用户和Apretude转换者[5][9] * LLY的GLP-1药物(Mounjaro/Zepbound)增长强劲 Zepbound周处方量42.93万份 同比增长191%[20][23][25] * 生物类似药加速替代：Stelara生物类似药Yesintek份额达8% Wezlana占5% Prolia生物类似药Jubbonti份额1%[13] * 免疫学药物定价分析显示Skyrizi每处方价格随适应症扩展下降 Tremfya因渠道数据限制可靠性低[11][186][190] **其他重要内容** * 阿尔茨海默药物Kisunla(LLY)和Leqembi(BIIB/Eisai)销售图表见附录[10] * COVID疫苗处方量持续下滑 Comirnaty周处方量同比下降94%[23] * 抗凝血剂市场Eliquis份额70% 主导地位稳固[99][101] * GLP-1类药物占糖尿病市场28%份额 Ozempic周处方量58.07万份[119][120][152] * 数据限制影响：Humira、Vyndaqel、Skyrizi、Evenity等因供应商合同限制导致处方量数据不完整[27][45] **数据附录** * 处方量单位：TRx(总处方量,含续方) NRx(新处方量) EUTRx(扩展单位处方量)[28] * 货币单位：美元 价格均为净价格(扣除折扣后)[3][4][43] * 生物类似药时间线：涵盖Humira、Lucentis、Neulasta等17个主要品牌的生物类似药批准和上市日期[51]

活动概况 - 活动于9月4日在惠州举办 由中国国际进口博览局 国务院国资委国际合作局 华润集团 国家会展中心共同主办 [1] - 活动为进博会走进央企第二站 聚焦大健康领域 吸引30余家世界500强及行业龙头参与 包括强生 辉瑞 宜家等企业 [1] - 活动主题为走进华润共健未来 旨在通过精准对接放大进博会溢出效应 深化央企与国际伙伴合作 [1] 华润业务参与 - 华润集团旗下七大业务部门参与对接 包括华润医药商业 华润三九 东阿阿胶 华润江中 华润双鹤 华润健康 华润置地 [1] - 七大业务部门在现场释放进口采购需求 与20余家进博会参展商进行供需对接 [1] 外资企业中国市场拓展 - 欧洲企业通过进博会链接在华经销商 代理商 优质客户等资源 高效拓展中国市场 [2] - 进博会帮助外资企业将展品新品变为进口商品 进入中国消费市场 [2] - 受访企业普遍看好中国市场增速 认为中国仍保持超大市场规模优势 [2] 市场准入与政策环境 - 部分企业指出中国对某些医疗设备缺乏匹配的准入标准 限制先进产品面向更广泛消费者群体 [2] - 企业期待未来准入过程更多参考国际标准 以提升产品市场渗透率 [2]

临床研究结果 - RYBREVANT联合LAZCLUZE在一线治疗EGFR突变晚期非小细胞肺癌的3期MARIPOSA研究中显示总生存期显著改善 风险比0.75 中位总生存期预计超过4年 较奥希替尼单药治疗延长超过1年[1][2] - 中位随访37.8个月时 联合治疗组中位总生存期尚未达到 95%置信区间为42.9个月至不可估计[2] - 该联合方案通过三重作用机制改变疾病自然史 包括双角度靶向EGFR突变 阻断MET以及激活免疫系统[3] 治疗方案特性 - 该联合方案为无化疗组合 可避免常见耐药类型并将化疗保留至后线治疗[3] - 安全性特征与主要分析一致 未出现新的安全信号 大多数3级或以上不良事件发生在治疗早期[4] - 研究显示预防性措施可降低皮肤反应 输注相关反应和静脉血栓栓塞事件风险[4] 研究设计 - MARIPOSA研究纳入1,074例患者 评估联合方案对比奥希替尼及LAZCLUZE单药在EGFR ex19del或L858R突变患者中的疗效[6] - 主要终点为盲态独立中心评估的无进展生存期 次要终点包括总生存期 总体缓解率和缓解持续时间[6] 药物批准情况 - RYBREVANT在美国 欧洲等多市场获批与LAZCLUZE联合用于EGFR ex19del或L858R突变患者的一线治疗[9] - RYBREVANT皮下制剂在欧洲获批与LAZCLUZE联合用于一线治疗 美国FDA已受理该适应症的生物制剂许可申请[11] - LAZCLUZE为口服第三代脑渗透性EGFR TKI 靶向T790M突变和激活EGFR突变[14] 疾病背景 - 非小细胞肺癌占所有肺癌病例80-85% EGFR突变见于10-15%西方腺癌患者和40-50%亚洲患者[16] - EGFR ex19del或L858R为最常见EGFR突变 EGFR exon20插入突变为第三大常见激活突变[16] - 接受EGFR TKI治疗的晚期EGFR突变NSCLC患者五年生存率低于20%[16] 临床指南推荐 - NCCN指南将RYBREVANT联合LAZCLUZE作为EGFR ex19del或L858R突变患者一线治疗的1类推荐[12] - RYBREVANT联合化疗被列为奥希替尼治疗后进展患者的1类推荐[12] 研发管线 - RYBREVANT正在多项临床试验中评估 包括MARIPOSA-2 PAPILLON PALOMA-3等研究[12] - 这些研究涵盖不同治疗线数和联合方案 包括与化疗 MET抑制剂及免疫疗法的组合[12]